Allen Feng, Ph.D
Chief Scientific Officer
Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to joining HebeCell, he was the Director of Cell Biology of Semma Therapeutics, where Dr. Feng played a key role in the successful establishment of the process development operation. Prior to Semma, Dr. Feng worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (a US subsidiary of Merck, KGaA). Before joining Millipore, Dr. Feng was Director and Senior Scientist at Advanced Cell Technology (later became Ocata Therapeutics and Astellas). At Advanced Cell Technology, Dr. Feng was the major contributor and inventor of several key discoveries such as the patented Hemangioblast technology (published in Nature Methods); generation of donorless red blood cells (published in Blood); and generation of HLA-negative functional platelets from human pluripotent stem cells (published in Stem Cell Reports).
Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to joining HebeCell, he was the Director of Cell Biology of Semma Therapeutics, where Dr. Feng played a key role in the successful establishment of the process development operation. Prior to Semma, Dr. Feng worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (a US subsidiary of Merck, KGaA). Before joining Millipore, Dr. Feng was Director and Senior Scientist at Advanced Cell Technology (later became Ocata Therapeutics and Astellas). At Advanced Cell Technology, Dr. Feng was the major contributor and inventor of several key discoveries such as the patented Hemangioblast technology (published in Nature Methods); generation of donorless red blood cells (published in Blood); and generation of HLA-negative functional platelets from human pluripotent stem cells (published in Stem Cell Reports).
